|
T1845 |
B-Raf IN 1
|
|
Raf
|
|
B-Raf IN 1 is a B-Raf (IC50: 24 nM) and c-Raf (IC50: 25 nM) inhibitor. |
|
T40284 |
B-Raf IN 2
|
|
Raf
|
|
B-Raf IN 2, compound Ia, is a highly effective and specific inhibitor of BRAF. It exhibits significant potential for cancer research. |
|
T19802 |
B-Raf IN 11
|
|
Raf
|
|
B-Raf IN 11 is a novel selective inhibitor. The DFG-in conformation of the B-Raf kinase V600E mutant is superior to the DFG-out conformation in colorectal cancer. |
|
T2074 |
Raf inhibitor 1
|
B-Raf inhibitor 1 |
Raf
|
|
B-Raf inhibitor 1 (B-Raf inhibitor 1) is a potent and selective B-Raf inhibitor. |
|
T4167 |
Raf inhibitor 1 dihydrochloride
|
B-Raf inhibitor 1 dihydrochloride |
Raf
|
|
Raf inhibitor 1 dihydrochloride (B-Raf inhibitor 1 dihydrochloride) is a potent and selective B-Raf inhibitor. |
|
T78183 |
B-Raf IN 15
|
|
Raf
|
|
B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used in the study of melanoma and cancer, and can be optimized for use as a more effective BRA F inhibitor. |
|
T79830 |
B-Raf IN 16
|
|
Raf
|
|
B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research. |
|
T72070 |
B-Raf IN 14
|
|
Bradykinin Receptor
|
|
B-Raf IN 14 is a BRAF inhibitor. |
|
T63333 |
Uplarafenib
|
B-Raf IN 10 |
Raf
|
|
Uplarafenib (B-Raf IN 10) is a potent BRAF inhibitor with an IC50 in the range of 50-100 nM.B-Raf IN 10 has antitumor activity that may affect cell proliferation and differentiation did not, and can be used to study soli... |
|
T67862 |
B-Raf IN 13
|
|
Raf
|
|
B-Raf IN 13 is a potent B-Raf inhibitor with anticancer activity.B-Raf IN 13 has an IC50 of 3.55 nM in the BRAF V600E enzyme assay. |
|
T12556 |
PROTAC B-Raf degrader 1
|
|
Raf
,
PROTACs
|
|
PROTAC B-Raf degrader 1 is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf,PROTAC B-Raf degrader 1 With anti-cancer activity. |
|
T41003 |
KG5
|
|
Raf
,
FLT
,
PDGFR
,
c-Kit
|
|
KG5 is a dual allosteric inhibitor of PDGFRβ and B-Raf with a Kd of 520 nM and 300 nM for PDGFRβ and PDGFRα. KG5 inhibits FLT3, KIT, and c-Raf with anticancer and antiangiogenic activities. |
|
T64116 |
B-Raf IN 5
|
|
|
|
B-Raf IN 5 is a potent inhibitor of the protein kinase B-Raf (IC50: 2.0 nM). B-Raf IN 5 resists rapid metabolism and does not bind to the secondary target PXR. |
|
T60727 |
B-Raf IN 8
|
|
|
|
B-Raf IN 8 (compound 7g) is a potent inhibitor of B-Raf (IC 50 = 70.65 nM). B-Raf IN 8 shows antitumor activity which has IC 50 values of 9.78, 13.78, 18.52 and 29.85 μM against hepatocellular carcinoma (HEPG-2), colon ... |
|
T61935 |
B-Raf IN 9
|
|
|
|
B-Raf IN 9 (compound 8b) is an effective B-Raf inhibitor (IC50=24.79 nM). B-Raf IN 9 blocks cell cycle at G2/M phase and induces apoptosis. B-Raf IN 9 showed potent anti-tumor activity on human prostate cancer PC-3 cells... |
|
T63855 |
B-Raf IN 6
|
|
|
|
B-Raf IN 6 is a potent inhibitor (IC50: 1.7 nM) of the protein kinase B-Raf, which does not bind the secondary target PXR and is resistant to rapid metabolism.B-Raf IN 6 has shown research potential in cancer diseases. |
|
T60933 |
B-Raf IN 7
|
|
|
|
B-Raf IN 7 (compound 6a) is a potent inhibitor of B-Raf with an IC 50 of 110.23 nM. B-Raf IN 7 has antitumor activity against colon carcinoma cells(HCT-116), mammary gland cells(MCF-7), hepatocellular carcinoma cells(HEP... |
|
T5634 |
Belvarafenib
|
|
Raf
|
|
Belvarafenib is a potent and pan RAF inhibitor with antineoplastic activity. The IC50 values of Belvarafenib are 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. |
|
T2295 |
SB-590885
|
|
Raf
|
|
SB590885 is an effective B-Raf inhibitor (Ki: 0.16 nM, in a cell-free assay). The selectivity of SB590885 for B-Raf is 11-fold greater over c-Raf, no acts to other human kinases. |
|
T6320 |
GDC-0879
|
GDC 0879,AR-00341677,GDC0879 |
Raf
|
|
GDC-0879 (AR-00341677) is a novel, potent and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well. |
|
T8474 |
Dabrafenib Mesylate
|
GSK 2118436B,GSK2118436 Mesylate |
Raf
|
|
Dabrafenib Mesylate (GSK2118436 Mesylate) is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively). |
|
T1903 |
Dabrafenib
|
GSK2118436A,GSK2118436 |
Raf
|
|
Dabrafenib (GSK2118436A) is a Raf inhibitor that inhibits C-Raf and B-RafV600E (IC50=5/0.6 nM) and is ATP-competitive. Dabrafenib exhibits antitumor activity for the treatment of B-RafV600E-mutated melanoma. |
|
T3711 |
RAF709
|
|
Raf
|
|
RAF709 is a novel Raf kinase inhibitor with IC50s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively. |
|
T6882 |
LY3009120
|
DP-4978 |
Raf
,
Autophagy
|
|
LY3009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1. |
|
T6296 |
RAF265
|
CHIR-265 |
Apoptosis
,
Raf
,
VEGFR
,
Autophagy
|
|
RAF265 (CHIR-265) (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM. Phase 2. |
|
T15794 |
LUT014
|
|
Raf
|
|
LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment. |
|
T2473 |
PLX-4720
|
PLX4720 |
Raf
|
|
PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations). |
|
T6318 |
AZ 628
|
|
Apoptosis
,
Raf
|
|
AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc. |
|
T0093 |
Sorafenib tosylate
|
Bay 43-9006 |
Apoptosis
,
Raf
,
VEGFR
,
FLT
,
Ferroptosis
,
PDGFR
,
c-Kit
,
Autophagy
|
|
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf). |
|
T0093L |
Sorafenib
|
Bay 43-9006 |
Apoptosis
,
Raf
,
VEGFR
,
FLT
,
Ferroptosis
,
PDGFR
,
c-Kit
,
Autophagy
|
|
Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. Sorafenib has antitumor activity... |
|
T4133 |
CCT196969
|
|
Raf
,
Src
|
|
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs. |
|
T2382 |
Vemurafenib
|
RO5185426,RG7204,PLX4032 |
Raf
,
MAPK
,
ACK
,
Src
,
Autophagy
|
|
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive... |
|
T10599 |
BRAF inhibitor
|
|
Raf
|
|
BRAF inhibitor is an inhibitor of B-Raf. |
|
T11898 |
LXH254
|
|
Raf
|
|
LXH254 is a potent C-Raf and B-Raf inhibitor. |
|
T1792L |
Regorafenib monohydrate
|
|
Raf
,
VEGFR
,
c-RET
,
PDGFR
,
c-Kit
,
Autophagy
|
|
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respect... |
|
T16909 |
Donafenib
|
Sorafenib (D3),Bay 43-9006 (D3),Sorafenib-d3 |
Raf
,
VEGFR
|
|
Donafenib (Bay 43-9006 (D3)) is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively). |
|
T8654 |
Plx-4032
|
Vemurafenib |
Raf
|
|
Plx-4032 (Vemurafenib) is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. |
|
T3579 |
PLX8394
|
|
Raf
|
|
PLX8394 is an orally active inhibitor of serine/threonine-protein kinase B-Raf (BRAF) protein. PLX8394 can selectively bind to and inhibit the activity of both wild-type and mutated forms of BRAF, then inhibit the prolif... |
|
T38511 |
AWL-II-38.3
|
|
Ephrin Receptor
|
|
AWL-II-38.3 is a highly effective inhibitor of EphA3, a receptor for ephrin-A. It demonstrates potent kinase inhibitory activity against EphA3 and does not show significant cellular activity against Src-family kinases or... |
|
T2617 |
SNS-314 Mesylate
|
SNS-314 |
Aurora Kinase
|
|
SNS-314 Mesylate (SNS-314) is an effective and specific Aurora A/B/C inhibitor (IC50: 9/31/3 nM). It is less inhibition of Trk A/B, Fms, Flt4, c-Raf, Axl, and DDR2. |
|
T22341 |
GSK-114
|
|
Others
|
|
GSK-114, a selective inhibitor of TNNI3 Interacting Kinase (TNNI3K) with IC50 of 25 nM, shows significant bias for TNNI3K over B-Raf with IC50 of 1000 nM, exceptional broad spectrum kinase selectivity and adequate oral e... |
|
T6277 |
Doramapimod
|
BIRB 796 |
Raf
,
p38 MAPK
,
Autophagy
|
|
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70. |
|
T22436 |
Takeda-6d
|
|
VEGFR
|
|
Takeda-6d, a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits B-RAF and VEGFR2 with IC50 of 7.0nM and 2.2nM. |
|
TQ0048 |
BI-882370
|
|
Raf
|
|
BI-882370 is a specific RAF kinase inhibitor. BI-882370 inhibits the oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases (IC50s: 0.4, 0.8 and 0.6 nM). BI-882370 also inhibits SRC family kinases. |
|
T6487 |
Encorafenib
|
LGX818 |
Raf
|
|
Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity. |
|
T12685 |
RAF mutant-IN-1
|
|
Others
|
|
RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively). |
|
T1886 |
TAK-632
|
|
Raf
,
FGFR
,
PDGFR
,
Aurora Kinase
|
|
TAK-632 is a potent pan-Raf inhibitor. |
|
T15480 |
HG6-64-1
|
HMSL 10017-101-1 |
Others
|
|
HG6-64-1 is a potent and selective inhibitor of B-Raf (IC50: 0.09 μM on B-raf V600E transformed Ba/F3 cells). |
|
T27454 |
GSK2008607
|
|
Raf
|
|
GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers. |
|
T6971 |
Ro 5126766
|
CH5126766,Avutometinib,VS-6766,RO5126766 |
Raf
,
MEK
|
|
RO5126766 (CH5126766) is a dual RAF/MEK inhibitor with IC50 of 8.2 nM, 19 nM, 56 nM, and 160 nM for BRAF V600E, BRAF, CRAF, and MEK1, respectively. Phase 1. |
